News & Updates
Filter by Specialty:
Dostarlimab a miraculous cure for mismatch repair-deficient, locally advanced rectal cancer?
Use of dostarlimab, a single-agent programmed death 1 (PD-1) monoclonal antibody, appears to have successfully cured mismatch repair-deficient, locally advanced rectal cancer, reports a recent study.
Dostarlimab a miraculous cure for mismatch repair-deficient, locally advanced rectal cancer?
16 Jun 2022
Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
The investigational microbiota-based live biotherapeutic RBX2660 is safe and averts repeat episodes of Clostridioides difficile infection (CDI) across patient populations with comorbid conditions, as shown in a study presented at Digestive Disease Week (DDW) 2022.
Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
07 Jun 2022
Does IBS elevate long-term risk of cancer?
People with irritable bowel syndrome (IBS) are not at increased overall risk of cancer relative to the general population, reveals a study. On the contrary, those with IBS appear to have a lower risk of incident colorectal cancer (CRC) and cancer-specific mortality.
Does IBS elevate long-term risk of cancer?
07 Jun 2022
H. pylori eradication suppresses long-term gastric cancer risk
Helicobacter pylori eradication treatment leads to large reductions in the risk of gastric cancer and lower rates of associated deaths over 10 years of follow-up, according to a recent meta-analysis.
